Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research-Guwahati, Guwahati, Assam, India.
Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research-Hajipur, Hajipur, Bihar, India.
Phytother Res. 2021 Dec;35(12):6802-6812. doi: 10.1002/ptr.7265. Epub 2021 Sep 1.
This systematic review and meta-analysis aims to find the effect of Gymnema sylvestre (GS) supplementation on glycemic control in type-2 diabetes mellitus (T2DM). PubMed, Cochrane library, Google Scholar, and Science Direct were searched from inception to June 2020 to identify the studies that reported GS supplementation on glycemic parameters. Standardized mean difference (SMD) was calculated by comparing the post-intervention data with baseline data. SMDs with 95% confidence intervals (CIs) were pooled using a random-effects model. Our meta-analysis consisting of 10 studies with a total of 419 participants showed that GS supplementation significantly reduces fasting blood glucose (FBG) (SMD 1.57 mg/dl, 95% CI 2.22 to -0.93, p < .0001, I 90%), postprandial blood glucose (PPBG) (SMD 1.04 mg/dl, 95% CI 1.53 to -0.54, p < .0001, I 80%), and glycated haemoglobin (HbA1c) (SMD 3.91, 95% CI 7.35 to -0.16%, p < .0001, I 99%) compared to baseline. Further, our study also found that GS significantly reduces triglycerides (SMD 1.81 mg/dl, 95% CI 2.95 to -0.66, p < .0001, I : 96%), and total cholesterol (SMD 4.10 mg/dl, 95% CI 7.21 to -0.99, p < .0001, I : 98%) compared to baseline. Our study shows that GS supplementation is effective in improving glycemic control and reducing lipid levels in T2DM patients and suggests that such supplementation might be used as an effective therapy for the management of T2DM and its associated complications to an extent.
本系统评价和荟萃分析旨在探讨匙羹藤（GS）补充剂对 2 型糖尿病（T2DM）患者血糖控制的影响。我们检索了 PubMed、Cochrane 图书馆、Google Scholar 和 Science Direct，从建库至 2020 年 6 月，以确定报告 GS 补充剂对血糖参数影响的研究。通过比较干预后数据与基线数据，计算标准化均数差（SMD）。使用随机效应模型汇总具有 95%置信区间（CI）的 SMD。我们的荟萃分析包括 10 项研究，共 419 名参与者，结果表明，GS 补充剂可显著降低空腹血糖（FBG）（SMD 为 1.57mg/dl，95%CI 为 2.22 至 -0.93，p<0.0001，I 90%）、餐后血糖（PPBG）（SMD 为 1.04mg/dl，95%CI 为 1.53 至 -0.54，p<0.0001，I 80%）和糖化血红蛋白（HbA1c）（SMD 为 3.91，95%CI 为 7.35 至 -0.16%，p<0.0001，I 99%）与基线相比。此外，我们的研究还发现，GS 显著降低甘油三酯（SMD 为 1.81mg/dl，95%CI 为 2.95 至 -0.66，p<0.0001，I 96%）和总胆固醇（SMD 为 4.10mg/dl，95%CI 为 7.21 至 -0.99，p<0.0001，I 98%）与基线相比。我们的研究表明，GS 补充剂可有效改善 T2DM 患者的血糖控制和降低血脂水平，并提示此类补充剂可能在一定程度上可作为 T2DM 及其相关并发症管理的有效治疗方法。
